Spectroscopy in Parkinson Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-10-31

Study Completion Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the study is to determine the utility of blood plasma infrared spectroscopy (biospectroscopy) in distinguishing subjects with idiopathic Parkinson's disease from healthy controls.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Electromyography Signals as Biomarkers for Parkinson's Disease

NCT02168504

Parkinson's Disease

COMPLETED

Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families

NCT00273351

Parkinson Disease Parkinsonian Syndrome

COMPLETED PHASE2

A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease

NCT00117195

Parkinson's Disease Parkinsonian Syndrome

COMPLETED

Biomarker Discovery in Parkinson's Disease

NCT02016092

Parkinson's Disease

UNKNOWN

Measures of Motor Impairment in Early Parkinson's Disease

NCT00291265

Parkinson's Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Oxidative stress has been implicated as a factor in the pathogenesis of Parkinson's disease (PD). The overall goal of this proposal is to use a novel metabolomics platform, based on near infrared biospectroscopy, to detect oxidatively modified blood plasma constituents. These spectral findings can be used to model the degree of oxidative stress with a modeled "stress index" that may distinguish PD cases from healthy elderly controls.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PostCEPT Subjects

Subjects with current Parkinson Disease Diagnosis currently enrolled in PostCEPT study

Blood draw

Intervention Type OTHER

Blood draw, two tubes, used for isolation of cell-free blood plasma

Control Subjects

Non-blood relatives of PostCEPT Subjects matched for age and other demographics

Blood draw

Intervention Type OTHER

Blood draw, two tubes, used for isolation of cell-free blood plasma

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood draw

Blood draw, two tubes, used for isolation of cell-free blood plasma

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

PD Subjects:

1. PostCEPT subjects with a diagnosis of PD based on UK Brain Bank criteria.
2. Willing and able to provide informed consent.

Healthy Controls:

1. No current diagnosis or known history of a neurological disease/disorder.
2. Non-blood relative of a patient or subject at the site who has diagnosis of PD (may include healthy controls from the PROBE study).
3. No first degree relatives with diagnosis of PD
4. MoCA score \> 26.
5. Age \> 45.
6. Willing and able to provide informed consent.

Minimum Eligible Age

46 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes